J. Gall

发表

A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.

B. Graham, M. Chen, J. S. Chang, 2010, Journal of immunological methods.

Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials

D. Brough, R. Koup, M. Roederer, 2009, Journal of Virology.

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

J. Mascola, D. Baltimore, E. Boritz, 2022, Nature Medicine.

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.

J. Mascola, A. Namboodiri, R. Koup, 2019, The lancet. HIV.

Enteric Species F Human Adenoviruses use Laminin-Binding Integrins as Co-Receptors for Infection of Ht-29 Cells

J. Heino, J. Gall, A. Mould, 2018, Scientific Reports.

Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.

J. Gall, Ping Chen, C. King, 2010, Vaccine.

Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes

L. Leinwand, J. Gall, A. Kass-Eisler, 1996, Journal of virology.

Alternate serotype adenovector provides long-term therapeutic gene expression in the eye

D. Brough, J. Gall, L. Wei, 2008, Molecular vision.

Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity

G. Nabel, M. Kanekiyo, J. Gall, 2009, Journal of Virology.

Previous Influenza Exposure Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with

J. Whittle, G. Nabel, P. McTamney, 2012 .

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

J. Mascola, R. Bailer, B. Graham, 2021, The Lancet. Respiratory medicine.

A proof of concept for structure-based vaccine design targeting RSV in humans

J. Mascola, P. Kwong, B. Graham, 2019, Science.

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114: A Phase 1 Trial of a Therapeutic Monoclonal Antibody Targeting Ebola Virus Glycoprotein

J. Mascola, R. Koup, N. Sullivan, 2019 .

Subgroup B and F Fiber Chimeras Eliminate Normal Adenovirus Type 5 Vector Transduction In Vitro and In Vivo

J. Gall, J. Schoggins, E. Falck-Pedersen, 2003, Journal of Virology.

A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape

J. Mascola, R. Koup, N. Sullivan, 2022, bioRxiv : the preprint server for biology.

Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen

J. Mascola, G. Chuang, Reda Rawi, 2020, Scientific Reports.

Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors

R. Crystal, J. Gall, L. Old, 1997 .

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

J. Mascola, R. Koup, T. Zhou, 2022, EClinicalMedicine.

Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype

J. Gall, E. Falck-Pedersen, R. Crystal, 1998, Journal of Virology.

Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization

R. Koup, M. McElrath, G. Nabel, 2009, Journal of Virology.

Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.

R. Crystal, J. Gall, L. Old, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

J. Mascola, Zonghui Hu, A. McDermott, 2022, The New England journal of medicine.

A Monoclonal Antibody for Malaria Prevention.

J. Mascola, Zonghui Hu, A. McDermott, 2021, The New England journal of medicine.

Characterization of human adenovirus 35 and derivation of complex vectors

D. Brough, G. Nabel, J. Gall, 2010, Virology Journal.

Differential Speciﬁcity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization (cid:1)

R. Koup, M. McElrath, G. Nabel, 2009 .

Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes

D. Brough, J. Gall, D. McVey, 2007, Molecular biotechnology.

Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method

M. Roederer, J. Gall, Srinivas S. Rao, 2011, Respiratory research.

Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.

D. Brough, B. Graham, D. Rangel, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Circumventing the immune response to adenovirus-mediated gene therapy.

J. Gall, A. Kass-Eisler, E. Falck-Pedersen, 1996, Gene therapy.

Adenovirus Vectors Hexon-Modified That Improves the Yields of Identification of a Suppressor Mutation

D. Brough, J. Gall, D. McVey, 2014 .

Identification of a Suppressor Mutation That Improves the Yields of Hexon-Modified Adenovirus Vectors

D. Brough, J. Gall, D. McVey, 2013, Journal of Virology.

Identiﬁcation of a Suppressor Mutation That Improves the Yields of Hexon-Modiﬁed Adenovirus Vectors

D. Brough, J. Gall, D. McVey, 2013 .

Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells

G. Nabel, J. Gall, W. Kong, 2007, PLoS pathogens.

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Mascola, Juan Li, R. Koup, 2022, bioRxiv.

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

S. Buchbinder, M. McElrath, G. Nabel, 2012, PLoS ONE.

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

S. Buchbinder, M. McElrath, G. Nabel, 2012, PloS one.

Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

D. Brough, G. Nabel, J. Gall, 2007, Vaccine.

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

P. Earl, B. Moss, G. Chuang, 2022, bioRxiv.

Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation

R. Koup, J. Gall, G. Mcinerney, 2011, Proceedings of the National Academy of Sciences.

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Daniel E. Zak, Kylie M. Quinn, A. Folgori, 2015, The Journal of clinical investigation.

Enhanced Induction of Intestinal Cellular Immunity by Oral Priming with Enteric Adenovirus 41 Vectors

G. Nabel, M. Kanekiyo, J. Gall, 2008, Journal of Virology.

Type I IFN Induced by Adenovirus Serotypes 28 and 35 Has Multiple Effects on T Cell Immunogenicity

R. Koup, E. Gostick, R. Sékaly, 2012, The Journal of Immunology.

CD8+ T Cell Responses following Replication-Defective Adenovirus Serotype 5 Immunization Are Dependent on CD11c+ Dendritic Cells but Show Redundancy in Their Requirement of TLR and Nucleotide-Binding Oligomerization Domain-Like Receptor Signaling

Kylie M. Quinn, B. Pulendran, A. Iwasaki, 2010, The Journal of Immunology.

Domain-Like Receptor Signaling Nucleotide-Binding Oligomerization Their Requirement of TLR and Dendritic Cells but Show Redundancy in + Immunization Are Dependent on CD 11 c Replication-Defective Adenovirus Serotype 5 T Cell Responses following + CD 8 Spies and

Sudhir, Kylie M. Quinn, B. Pulendran, 2010 .

Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization

Kylie M. Quinn, B. Moss, A. Folgori, 2013, The Journal of Immunology.

Immunization Recombinant Adenoviral Vector Human-, Simian-, and Chimpanzee-derived T Cells following + Gag-specific Cd8 of Simian Immunodeficiency Virus Quality, Phenotype, and Protective Capacity Comparative Analysis of the Magnitude

A. Folgori, R. Koup, M. Roederer, 2022 .

Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates

J. Mascola, N. Letvin, G. Nabel, 2012, Journal of Virology.

Adenoviruses isolated from wild gorillas are closely related to human species C viruses.

D. Brough, D. Rangel, J. Gall, 2013, Virology.

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

J. Mascola, R. Koup, C. Andrews, 2023, The Lancet.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

J. Mascola, R. Koup, C. Andrews, 2006, The Journal of infectious diseases.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

J. Mascola, R. Koup, C. Andrews, 2019, The Lancet.

The Number of Toll-Like Receptor 9-Agonist Motifs in the Adenovirus Genome Correlates with Induction of Dendritic Cell Maturation by Adenovirus Immune Complexes

G. Pantaleo, A. Harari, J. Gall, 2012, Journal of Virology.

Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1

J. Mascola, R. Koup, Baoshan Zhang, 2022, Vaccines.

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

J. Mascola, R. Koup, J. Casazza, 2022, Nature Medicine.

Development of ecdysone-regulated lentiviral vectors.

R. Evans, I. Verma, J. Gall, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development.

J. Mascola, G. Nabel, J. Gall, 2015, Vaccine.

Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency

Bradford W Tippett, Baoshan Zhang, N. Doria-Rose, 2022, Scientific Reports.

Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development

N. Doria-Rose, J. Gall, Vera B. Ivleva, 2022, Biotechnology progress.

Alternate serotype adenovector provides long-term therapeutic gene expression in the eye

D. Brough, J. Gall, L. Wei, 2008, Molecular vision.

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Carmen M. Graves, J. Mascola, R. Koup, 2023, Science Translational Medicine.

Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression.

R. Koup, J. Gall, N. Björkström, 2014, Vaccine.

Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure

J. Whittle, G. Nabel, P. McTamney, 2012, Science Translational Medicine.

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.

J. Mascola, T. Pierson, R. Koup, 2020, JAMA.

Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.

J. Gall, Q. Paula Lei, Victor Gavrilov, 2023, Vaccine.

Site-Specific Fluorescent Labeling of Hemagglutinin-Specific Antigen Binding Fragment through Amine Chemistry Revealed by Mass Spectrometry.

J. Gall, Vera B. Ivleva, Q. P. Lei, 2023, Journal of the American Society for Mass Spectrometry.

Characterization of Flu MOSAIC nanoparticle vaccine candidate using high performance size-exclusion chromatography to support vaccine process development.

J. Gall, Y. Tsybovsky, Q. Paula Lei, 2023, Vaccine.

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.

Zonghui Hu, A. McDermott, J. Gall, 2023, The Lancet. Infectious diseases.